ICMT | Isoprenylcysteine carboxyl methyltransferase | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
INSIG1 | Insulin induced gene 1 | Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
INSIG2 | Insulin induced gene 2 | Predicted membrane proteins
| | | | | Expressed in all |
ITPR2 | Inositol 1,4,5-trisphosphate receptor, type 2 | Plasma proteins Predicted membrane proteins
| | | | | Mixed |
JKAMP | JNK1/MAPK8-associated membrane protein | Cancer-related genes Predicted membrane proteins
| | | | | Expressed in all |
KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA4 | Potassium voltage-gated channel, shaker-related subfamily, member 4 | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNB2 | Potassium voltage-gated channel, Shab-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCND1 | Potassium voltage-gated channel, Shal-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH4 | Potassium voltage-gated channel, subfamily H (eag-related), member 4 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNH5 | Potassium voltage-gated channel, subfamily H (eag-related), member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH7 | Potassium voltage-gated channel, subfamily H (eag-related), member 7 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
KCNH8 | Potassium voltage-gated channel, subfamily H (eag-related), member 8 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK1 | Potassium channel, subfamily K, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCNK10 | Potassium channel, subfamily K, member 10 | Predicted membrane proteins
| | | | | Tissue enhanced |
KCNK12 | Potassium channel, subfamily K, member 12 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK13 | Potassium channel, subfamily K, member 13 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK16 | Potassium channel, subfamily K, member 16 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNK17 | Potassium channel, subfamily K, member 17 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK18 | Potassium channel, subfamily K, member 18 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNK2 | Potassium channel, subfamily K, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK5 | Potassium channel, subfamily K, member 5 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNMA1 | Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNQ4 | Potassium voltage-gated channel, KQT-like subfamily, member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNS2 | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNS3 | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNT1 | Potassium channel, subfamily T, member 1 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNT2 | Potassium channel, subfamily T, member 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNU1 | Potassium channel, subfamily U, member 1 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
KIAA0195 | KIAA0195 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
LMBRD1 | LMBR1 domain containing 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
LPCAT3 | Lysophosphatidylcholine acyltransferase 3 | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
LPPR1 | Lipid phosphate phosphatase-related protein type 1 | Predicted membrane proteins
| | | | | Group enriched |
LPPR3 | Hsa-mir-3187 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
LPPR4 | Lipid phosphate phosphatase-related protein type 4 | Enzymes Predicted membrane proteins
| | | | | Tissue enriched |
LPPR5 | Lipid phosphate phosphatase-related protein type 5 | Predicted membrane proteins
| | | | | Group enriched |